| 翻訳と辞書 |
PI-RADS
PI-RADS is an acronym for Prostate Imaging-Reporting and Data System, defining standards of high quality clinical service for multi-parametric Magnetic Resonance Imaging (mpMRI), including image creation and reporting.
== History ==
Since 2007, the AdMeTech Foundation's International Prostate MRI Working Group convened the key global experts, including members of the American College of Radiology (ACR) and European Society of Urogenital Radiology (ESUR). They reviewed emerging scientific evidence, developed research strategy and by early 2010, recommended development of the PI-RADS standardization, modeled after BI-RADS for Breast Imaging-Reporting and Data System, a quality assurance tool in breast imaging ,. The goal of this recommendation was to expedite large-scale clinical evaluation and implementation of high quality mpMRI for improved early detection and accurate diagnosis of clinically significant prostate cancer.
In response to this recommendation, ESUR developed PI-RADS version 1 (PI-RADS v1). Upon review of PI-RADS v1 in early 2011, AdMeTech Foundation's International Prostate MRI Working Group initiated development of global consensus for PI-RADS standardization (PI-RADS v2) and stimulated the interest of ACR and ESUR to ensure global acceptance and implementation. In late 2011, AdMeTech Foundation, ACR and ESUR formed a Joint Steering Committee, and by December 2014, developed and released an online version of PI-RADS v2, With support of the AdMeTech Foundation and ESUR, ACR trademarked the PI-RADS v2 version in order to provide leadership in education and training. In 2015, a scholarly article on PI-RADS v2 was accepted for publication in the Journal of European Urology; it was accompanied by the editorial detailing extensive differences between PI-RADS v1 and PI-RADS v2.
Since 2011, AdMeTech Foundation has also taken the lead in designing and managing a clinical trial, in partnership with the American College of Radiology Imaging Network, with the goal to provide a definitive scientific evidence on the value of mpMRI and PI-RADS v2 in addressing the central challenges in patient care: 1) Improving early detection of clinically significant prostate cancer, as defined by Gleason Grade 4 and higher and informed by volume of > 0.5 cc of the index lesion (which is considered the most clinically relevant); and 2) Reducing over-diagnosis and over-treatment of benign diseases and dormant cancer, which are not likely to cause harm in a man's lifetime. The first phase of this trial, which was undertaken by AdMeTech jointly with scientists of the Harvard Medical School (Brigham and Women's Hospital, Dana Farber Cancer Institute and the Massachusetts General Hospital), is expected to be completed in June 2016. If successful, this trial will expedite global clinical implementation of mpMRI and PI-RADS v2.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「PI-RADS」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|